• All
  • Important
  • Financial Update
  • Fund Raise
  • Board Meeting
  • Dividend/Bonus
  • JV/Acquisition
  • Investor Meet
  • Insider Trade
  • Pledging
  • Others
    ALPHA TRIBE

    Zydus Lifesciences Limited — Updates, 23-07-2026: Press Release

    23-07-2026 | 10:04 am

    Zydus gained approval for a Phase III trial of Desidustat for Sickle Cell Disease, collaborating with ICMR after successful Phase II. Desidustat holds Orphan Drug Designation, positioning it as a potential first-in-class therapy for this significant unmet medical need.

    No comments yet. Be the first to comment!

    All announcements from Zydus Lifesciences Limited